Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.

Hannah Fluhrer,Georg C Hutterer, Sylvia Golbeck, Michael Stidl,Tobias Niedrist,Renate Pichler,Johannes Mischinger,Maximilian Seles,Sebastian Mannweiler,Jasmin Spiegelberg,Thomas Bauernhofer,Philipp J Jost,Sascha Ahyai,Richard Zigeuner,Martin Pichler,Dominik A Barth

Therapeutic advances in medical oncology（2022）

引用 1|浏览25

暂无评分

摘要

Significant advances in the systemic medical treatment of mRCC during the recent decade and the introduction of immunotherapy exerted a major impact on patient outcomes in terms of OS in a real-life population.

查看译文

关键词

immunotherapy,interferon,outcomes,renal cell carcinoma,tyrosine kinase inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要